Ginsenoside
Rg1
(Rg1),
a
monomer
saponin
component,
is
one
of
the
components
with
highest
content
in
total
saponins
Panax
notoginseng,
and
has
variety
pharmacological
effects.
easily
degraded
by
enzymes
produced
intestinal
bacteria.
The
bioavailability
oral
tablets
only
1-20%,
it
eliminated
quickly
blood.
development
new
dosage
forms
routes
administration
ginsenoside
sustained
release
high
become
an
important
problem
to
be
solved
urgently.
study
liposomes
for
pulmonary
not
been
reported
so
far.
In
study,
were
prepared
film
dispersion-ultrasonic
method,
pharmacokinetic
parameters
rats
studied
infusion.
round
shape,
uniform
particle
size
was
2-3
μm,
encapsulation
efficiency
liposome
51.2%.
After
Rg1,
time
detected
longer
than
that
solution,
relative
lung
AUC
liposome/AUC
solution=122.67%.
results
could
provide
scientific
theoretical
experimental
basis
further
Rg1.
Advanced Healthcare Materials,
Год журнала:
2023,
Номер
13(4)
Опубликована: Ноя. 9, 2023
Diabetic
wounds
are
more
likely
to
develop
into
complex
and
severe
chronic
wounds.
The
objective
of
this
study
is
assess
a
reactive
oxygen
species
(ROS)-responsive
multifunctional
injectable
hydrogel
for
the
purpose
diabetic
wound
healing.
A
(HA@Cur@Ag)
successfully
synthesized
with
dual
antioxidant,
antibacterial,
anti-inflammatory
properties
by
crosslinking
thiol
hyaluronic
acid
(SH-HA)
disulfide-bonded
hyperbranched
polyethylene
glycol
(HB-PBHE)
through
Michael
addition;
while,
incorporating
curcumin
liposomes
silver
nanoparticles
(AgNPs).
HA@Cur@Ag
exhibits
favorable
biocompatibility,
degradability,
injectivity.
outcomes
in
vitro
vivo
experiments
demonstrate
that
can
effectively
be
loaded
release
liposomes,
as
well
ions,
thereby
facilitating
healing
multiple
mechanisms,
including
ROS
scavenging,
bactericidal
activity,
effects,
promotion
angiogenesis.
Transcriptome
sequencing
reveals
suppresses
activation
tumour
necrosis
factor
(TNF)/nuclear
κB
(NF-κB)
pathway
ameliorate
oxidative
stress
inflammation
These
findings
suggest
ROS-responsive
hydrogel,
which
possesses
ability
precisely
coordinate
integrate
intricate
biological
molecular
processes
involved
healing,
notable
potential
expediting
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2023,
Номер
11
Опубликована: Ноя. 17, 2023
Triple
positive
breast
cancer
(TPBC)
is
one
of
the
most
aggressive
cancer.
Due
to
unique
cell
phenotype,
aggressiveness,
metastatic
potential
and
lack
receptors
or
targets,
chemotherapy
choice
treatment
for
TNBC.
Doxorubicin
(DOX),
representative
agents
anthracycline
chemotherapy,
has
better
efficacy
in
patients
with
TNBC
(mTNBC).
DOX
anthracycline-based
regimens
have
higher
response
rates.
Nano-drug
delivery
systems
possess
targeting
ability
co-load,
deliver
release
chemotherapeutic
drugs,
active
gene
fragments
immune
enhancing
factors
effectively
inhibit
kill
tumor
cells.
Therefore,
advances
nano-drug
therapy
attracted
a
considerable
amount
attention
from
researchers.
In
this
article,
we
reviewed
progress
(e.g.,
Nanoparticles,
Liposomes,
Micelles,
Nanogels,
Dendrimers,
Exosomes,
etc.)
applied
We
also
summarize
current
clinical
trials
combined
checkpoint
inhibitors
(ICIS)
The
merits,
demerits
future
development
nanomedicine
are
envisioned,
aim
providing
new
class
safe
efficient
thoughts
Microsystems & Nanoengineering,
Год журнала:
2024,
Номер
10(1)
Опубликована: Авг. 20, 2024
Cancer,
a
multifaceted
and
diverse
ailment,
presents
formidable
obstacles
to
traditional
treatment
modalities.
Nanotechnology
novel
prospects
for
surmounting
these
challenges
through
its
capacity
facilitate
meticulous
regulated
administration
of
therapeutic
agents
malignant
cells
while
concurrently
modulating
the
immune
system
combat
neoplasms.
Bacteria
their
derivatives
have
emerged
as
highly
versatile
multifunctional
platforms
cancer
nanotherapy
within
realm
nanomaterials.
This
comprehensive
review
delves
into
groundbreaking
implementations
bacterial
nanotechnology
therapy.
encompasses
four
primary
facets:
utilization
bacteria
living
conveyors
medicinal
substances,
employment
components
that
stimulate
system,
deployment
vectors
tools
delivering
genetic
material,
development
bacteria-derived
nano-drugs
intelligent
nano-medications.
Furthermore,
we
elucidate
merits
modalities
operation
pertaining
nano-systems,
along
with
synergize
other
cutting-edge
nanotechnologies,
such
CRISPR-Cas
systems.
Additionally,
offer
insightful
viewpoints
regarding
forthcoming
trajectories
this
expanding
domain.
It
is
our
deduction
embodies
propitious
innovative
paradigm
in
therapy,
which
has
potential
provide
numerous
advantages
synergistic
effects
enhancing
outcomes
quality
life
individuals
afflicted
cancer.
Food Science & Nutrition,
Год журнала:
2025,
Номер
13(3)
Опубликована: Март 1, 2025
ABSTRACT
Silibinin
(C
25
H
22
O
10
),
a
notable
bioactive
flavonolignans,
is
recognized
for
its
anticancer
properties.
However,
due
to
poor
water
solubility,
the
objective
of
this
study
was
design
and
synthesize
nanocarriers
enhance
solubility
silibinin
effective
delivery
AGS
gastric
cancer
cells.
This
details
synthesis
PEG
400
‐OA
nanoparticles
Various
physicochemical
techniques,
including
FT‐IR,
TGA,
EDX,
FE‐SEM,
TEM,
were
employed
characterize
silibinin‐loaded
(SLNs),
confirming
particle
size,
elemental
composition,
thermal
stability,
paramagnetic
The
effects
SLNs
assessed
using
MTT
assay,
scratch
test,
Q‐RT‐PCR.
exhibited
sizes
ranging
from
45
60
nm,
with
stability
below
110°C.
TEM
images
suggested
micelles/liposomes
structure
low
polydispersity
spherical
shape
particles.
EDX
analysis
revealed
presence
C,
O,
N,
P,
incorporation
phospholipids
(micelle/liposome)
within
SLNs.
IC
50
in
cells
determined
be
28.21
μg/mL.
Antimigration
SLNs's
demonstrated
through
downregulation
miR‐181a
upregulation
potential
targets
(
TGFB
,
SMAD3
β‐catenin
genes),
as
well
miR‐34a
target
E‐Cadherin
antimigration
gene).
findings
suggest
that
serve
targeted
Silibinin‐loaded
(SLNs)
appear
inhibit
cell
proliferation
migration
by
modulating
expressionof
miRNAs
their
mRNAs.
Pharmaceutics,
Год журнала:
2025,
Номер
17(4), С. 520 - 520
Опубликована: Апрель 16, 2025
Delta-like
3
(DLL3)
is
an
oncogenic
protein
aberrantly
expressed
in
several
tumors,
particularly
small-cell
lung
cancer.
DLL3-targeted
therapies
have
recently
made
significant
progress,
demonstrating
promising
preclinical
and
clinical
efficacy.
This
review
aims
to
explore
the
mechanisms,
challenges,
future
opportunities
associated
with
targeting
DLL3
for
cancer
treatment.
The
biological
characteristics
of
its
role
Notch
signaling
pathway
are
introduced
first,
delving
into
tumorigenesis
progression.
Next,
current
therapeutic
approaches
described,
including
antibody–drug
conjugates,
T
cell
engagers,
chimeric
antigen
receptor
cells,
radiopharmaceutical
therapy,
highlighting
their
effectiveness
safety
trials.
Despite
prospects,
difficulties
remain
use
as
a
target
due
tumor
heterogeneity,
development
resistance,
potential
adverse
effects,
barriers
patient
stratification.
Therefore,
combination
therapies,
innovative
drug
delivery
systems,
ongoing
trial
advancements
also
discussed.
Finally,
summarized,
importance
multidisciplinary
research
guide
application
optimization
this
emerging
treatment
strategy.
These
might
provide
new
options,
potentially
starting
era
Pharmacological Reviews,
Год журнала:
2024,
Номер
77(1), С. 100013 - 100013
Опубликована: Окт. 15, 2024
Arrhythmia
refers
to
irregularities
in
the
rate
and
rhythm
of
heart,
with
symptoms
spanning
from
mild
palpitations
life-threatening
arrhythmias
sudden
cardiac
death
(SCD).
The
complex
molecular
nature
complicates
selection
appropriate
treatment.
Current
therapies
involve
use
antiarrhythmic
drugs
(class
I-IV)
limited
efficacy
dangerous
side
effects
implantable
pacemakers
cardioverter-defibrillators
hardware-related
complications
inappropriate
shocks.
number
novel
drug
development
pipeline
has
decreased
substantially
during
last
decade
underscores
uncertainties
regarding
future
developments
this
field.
Consequently,
arrhythmia
treatment
poses
significant
challenges,
prompting
need
for
alternative
approaches.
Remarkably,
innovative
discovery
technologies
show
promise
helping
advance
therapies.
Here,
we
review
unique
characteristics
transformative
potential
emerging
that
offer
unprecedented
opportunities
transitioning
traditional
antiarrhythmics
next-generation
We
assess
stem
cell
technology,
emphasizing
utility
profiling
using
multi-omics,
high-throughput
screening,
advanced
computational
modeling
developing
treatments
tailored
precisely
individual
genetic
physiological
profiles.
insights
into
gene
therapy,
peptide
peptibody
approaches
delivery.
finally
discuss
strengths
weaknesses
such
techniques
reducing
adverse
enhancing
overall
outcomes,
leading
more
effective,
specific,
safer
Altogether,
comprehensive
overview
introduces
avenues
personalized
particular
emphasis
on
discovery,
aiming
landscape
prevention
SCD.
Significance
Statement
Arrhythmias
account
15–20%
deaths
worldwide.
However,
current
are
ineffective
effects.
field
underscoring
slow
progress
advancing
therapy
evolution
provide
information
how
technological
experimental
tools
can
help
accelerate
address
limitations
discovery.
